OrthoLazer Bets on Robotic Lasers to Standardize Drug-Free Pain Relief

WARSAW, Ind. – March 24, 2026 – As the demand for non-opioid pain solutions intensifies, OrthoLazer is making a significant move to standardize its care model, announcing an expansion of its exclusive Photobiomodulation (PBM) Therapy portfolio across its growing national network of orthopedic wellness centers. The initiative hinges on what the company calls "the most advanced robotic laser in the world," a proprietary technology aimed at delivering consistent, non-invasive pain relief from coast to coast.

This strategic push by the Warsaw-based company signals a broader shift in orthopedic care, moving away from a reliance on drugs and injections towards technology-driven, non-pharmacological alternatives. By ensuring every new "Your Orthopedic Wellness Center" is equipped with the same advanced PBM therapy system, OrthoLazer aims to create a scalable and replicable standard of care that it believes will differentiate it in a competitive market.

"By continuing to advance our exclusive PBM Therapy portfolio, we are strengthening a care model that differentiates Your Orthopedic Wellness Center locations and supports long-term growth," said Kenny Hancock, CEO of OrthoLazer, in a statement.

The Science of Healing with Light

At the core of OrthoLazer’s strategy is Photobiomodulation, a therapeutic modality with a substantial body of scientific evidence. PBM therapy, also known as low-level laser therapy, uses specific wavelengths of red and near-infrared light to penetrate tissue and stimulate cellular activity. This process is scientifically documented to reduce inflammation, accelerate healing, and provide significant pain relief at the source.

The field is supported by over 800 randomized controlled trials and thousands of academic papers. Notably, the American College of Physicians now recommends PBM for low back pain, and clinical reviews published in prestigious journals like The Lancet have highlighted its efficacy. Studies show PBM can decrease pain scores by an average of 32% compared to placebo treatments for a range of musculoskeletal conditions, including knee osteoarthritis, tendinopathies, and post-operative pain.

OrthoLazer's platform is built upon the FDA-cleared MLS M8 Robotic Laser. The company states this device is unique due to its robotic delivery system, which ensures a precise and homogeneous dose of light energy is applied across the entire treatment area. Unlike handheld devices that can lead to inconsistent application, the robotic arm automates the process, activating a larger volume of tissue and ensuring every patient receives an optimal, repeatable treatment. The technology emits pulsed energy, allowing cells to absorb photons without overheating, a key safety feature that minimizes risk and enhances patient comfort.

"Technology only matters if it improves the standard of care," noted Dr. Scott Sigman, Founder and Chief Medical Officer of OrthoLazer. "As OrthoLazer grows, a unified PBM Therapy approach allows each location to deliver the same high-quality patient experience in every market."

Scaling Precision Through a Standardized Franchise Model

OrthoLazer's announcement is as much a business strategy as it is a clinical one. The company operates on a franchise model, and the standardization of its core technology is crucial for scaling its "Your Orthopedic Wellness Center" brand nationally. By creating a turnkey system built around proprietary technology and evidence-informed protocols, the company aims to solve one of the biggest challenges in healthcare franchising: ensuring consistent quality and outcomes across disparate locations.

The initial investment for a franchisee ranges from approximately $414,000 to $522,000, a significant portion of which covers the advanced laser technology. In return, OrthoLazer provides a comprehensive support system, including a "proven 4-step training and support system," ongoing operational assistance through its OrthoLazer University, and guidance on marketing and business systems. This model is designed to attract orthopedic surgeons and entrepreneurs looking to tap into the growing market for alternative care.

The standardized PBM Therapy portfolio will be a mandatory feature in all new centers, while existing locations will have the option to adopt the advancements. This ensures a consistent brand promise for new patients while allowing established centers to evolve.

"By continuing to strengthen our exclusive PBM Therapy portfolio, we are ensuring that each location is equipped to deliver consistent care and meaningful differentiation as the network grows," stated Rod Mayer, President of OrthoLazer.

Meeting the Demand in a Post-Opioid Era

OrthoLazer's expansion is timed to capitalize on powerful currents in the U.S. healthcare system. The ongoing opioid crisis has created an urgent need and a strong patient desire for effective, non-addictive pain management solutions. The global laser therapy market reflects this shift, with projections estimating it will surge from around $5 billion in 2024 to nearly $8 billion by 2032.

Patient satisfaction data from OrthoLazer suggests the model is resonating. Internal surveys indicate that 93% of patients are pleased with their care, and 79% are happy with their treatment results. Testimonials frequently cite accelerated recovery from procedures like knee replacements, and significant relief from chronic conditions such as bursitis and arthritis, often eliminating the need for pain medication or corticosteroid injections.

This focus on non-invasive, drug-free treatment aligns with a broader movement towards patient-centered and preventative care. As patients become more proactive in their health decisions, options that offer recovery without downtime or the side effects of pharmaceuticals are increasingly attractive. OrthoLazer is betting that its combination of advanced technology, surgeon oversight, and a consistent patient experience will establish it as a leader in this new paradigm of orthopedic wellness. The company’s disciplined approach to aligning its exclusive technology with standardized protocols positions it to capture a significant share of a market that is actively seeking safer, more sustainable solutions for pain.